Search

The NHS in England is introducing a more efficient way of administering a treatment for HER2 positive early and metastatic breast cancer.  The new treatment is called Phesgo and is a combination of Perjeta (pertuzumab) and Herceptin (trastuzumab), two monoclonal antibodies.  Phesgo uses new ENHANZE technology to deliver a sub-cutaneous fixed dose injection which can be administered in less than ten minutes compared with the much longer time of up to three hours which is needed for the sequential infusion of the same drugs.  There is no difference in efficacy and the injection can even be administered by a qualified medical professional in the home.